N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry

Journal of Neurology

Volumn 254, Issue 5, 2007, Pages 631-637

  Jasperse, Bas ^a   Jakobs, Cornelis ^a   Eikelenboom, M Judith ^a   Dijkstra, Christine D ^a   Uitdehaag, Bernard M J ^a   Barkhof, Frederik ^a   Polman, Chris H ^a   Teunissen, Charlotte E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cerebrospinal fluid; Magnetic resonance imaging; Multiple sclerosis; N acetylaspartic acid

Indexed keywords

BIOLOGICAL MARKER; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LUMBAR PUNCTURE; MALE; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RATING SCALE; RELAPSE; REMISSION; STATISTICAL SIGNIFICANCE;

ADULT; ASPARTIC ACID; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 34249004265     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0415-5     Document Type: Article

References (29)

1. Baslow MH (2003) N-acetylaspartate in the vertebrate brain: Metabolism and function. Neurochem Rese 28:941-953
2. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W (2000) Acute axonal injury in multiple sclerosis - Correlation with demyelination and inflammation. Brain 123:1174-1183
3. Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp BD (2002) N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 51:51-58
4. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 48:893-901
5. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42:783-793
6. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122(Pt 5):871-882
7. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, Mcdonald WI (1994) Serial Proton Magnetic-Resonance Spectroscopy in Acute Multiple-Sclerosis Lesions. Brain 117:49-58
8. De Stefano N, Guidi L, Stromillo ML, Bartolozzi ML, Federico A (2003) Imaging neuronal and axonal degeneration in multiple sclerosis. Neurol Sci 24:S283-S286
9. De Stefano N, Iannucci G, Sormani MP, Guidi L, Bartolozzi ML, Comi G, Federico A, Filippi M (2002) MR correlates of cerebral atrophy in patients with multiple sclerosis. J Neurol 249:1072-1077
10. De Stefano N, Matthews PM, Fu LQ, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis - Results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469-1477
11. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65-70
12. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM (2000) Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 123(Pt 9):1845-1849
13. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399
14. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121:103-113
15. Jakobs C, ten Brink HJ, Langelaar SA, Zee T, Stellaard F, Macek M, Srsnova K, Srsen S, Kleijer WJ (1991) Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease. J Inherit Metab Dis 14:653-660
16. Kalkers NF, De Groot V, Lazeron RHC, Killestein J, Ader HJ, Barkhof F, Lankhorst GJ, Polman CH (2000) MS Functional Composite - Relation to disease phenotype and disability strata. Neurology 54:1233-1239
17. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157:267-276
18. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
19. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46:907-911
20. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:1676-1695
21. Oestreicher AB, De Graan PN, Gispen WH, Verhaagen J, Schrama LH (1997) B-50, the growth associated protein-43: modulation of cell morphology and communication in the nervous system. Prog Neurobiol 53:627-686
22. Poser CM, Paty DW, Scheinberg L, Mcdonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New Diagnostic-Criteria for Multiple-Sclerosis - Guidelines for Research Protocols. Ann Neurol 13:227-231
23. Smith SM, Zhang YY, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479-489
24. Teunissen CE, Dijkstra C, Polman C (2005) Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4:32-41
25. Teunissen CE, Dijkstra CD, Jasperse B, Barkhof F, Vanderstichele H, Vanmechelen E, Polman CH, Bo L (2006) Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. Neuropathol Appl Neurobiol 32:318-331
26. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285
27. Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12:295-302
28. van Walderveen MAA, Barkhof F, Pouwels PJW, van Schijndel RA, Polman CH, Castelijns JA (1999) Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 46:79-87
29. Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ (2005) MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 53:256-266